Advertisement

Topics

"Active Biotech Interim report January March 2018" Drugs and Medication Database: Page 5

22:22 EST 16th February 2019 | BioPortfolio

Here are the most relevant "Active Biotech Interim report January March 2018" Drugs and Medications that we have found in our database.

More Information about "Active Biotech Interim report January March 2018" on BioPortfolio

We have published hundreds of Active Biotech Interim report January March 2018 news stories on BioPortfolio along with dozens of Active Biotech Interim report January March 2018 Clinical Trials and PubMed Articles about Active Biotech Interim report January March 2018 for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Active Biotech Interim report January March 2018 Companies in our database. You can also find out about relevant Active Biotech Interim report January March 2018 Drugs and Medications on this site too.

Showing "Active Biotech Interim report January March 2018" Drugs and Medications 101–107 of 107

Possibly Relevant

Tremfya [janssen biotech, inc.]

These highlights do not include all the information needed to use TREMFYA safely and effectively. See full prescribing information for TREMFYA. TREMFYA (guselkumab) injection, for subcutaneous use Initial U.S. Approval: 2017

Tri-vit with fluoride drops [par pharmaceutical]

TRI-VIT WITH FLUORIDE 0.5 mg DROPS Rx only

Avc [meda pharmaceuticals]

NA

Cephalexin [redpharm drug, inc.]

NA

Cephalexin [redpharm drug, inc.]

NA

Alocril [allergan, inc.]

ALOCRIL (nedocromil sodium ophthalmic solution) 2% sterile

Mometasone furoate [glenmark pharmaceuticals inc., usa]

These highlights do not include all the information needed to use MOMETASONE FUROATE CREAM safely and effectively. See full prescribing information for MOMETASONE FUROATE CREAM. MOMETASONE FUROATE Cream, 0.1% for topical use Initial U.S. Approval: 1987



Advertisement
Quick Search
Advertisement
Advertisement